Exhibit 99.2



minovia | mitochondrial therapies

Investor Presentation
June 2025

Disclaimers

Disclaimers and Other Important Information

This presentation (this "Presentation") is being furnished solely to (i) recipients that are "qualified institutional buyers" as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), or institutional "accredited investors" (as defined in Rule 506 of Regulation D) and (ii) recipients in Israel who qualify as an investor listed in the first addendum of the Israeli Securities Law, 1968 (the "'Securities Law") (any such recipient in (i) and (ii), together with its subsidiaries and affiliates, the "Recipient") by Launch One Acquisition Corp., a Cayman Islands exempted company ("Launch"), and Minovia Therapeutics Ltd., an Israeli company limited by shares ("Minovia," and together with Launch, the "Parties") solely for informational purposes of considering the opportunity to participate in the proposed private placement of securities of Minovia and/or Launch (the "Offerings") in connection with a potential business combination between the Parties and related transactions (the "Business Combination" and together with the Offerings, the "Transactions"). By reading this Presentation, the Recipient will be deemed to have agreed to the obligations and restrictions set out below.

This Presentation and any oral statements made in connection with this Presentation do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities in any jurisdiction, or the solicitation of any proxy, vote, consent or approval in any jurisdiction, in connection with the Transactions, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This Presentation does not constitute any form of advice or a recommendation regarding any securities. Interested parties are advised to consult their own professional advisors in connection with making any investment decision. Any offer to sell securities pursuant to the Offerings will be made only pursuant to a definitive subscription agreement and related documentation and will be made in reliance on an exemption from registration under the Securities Act for offers and sales of securities that do not involve a public offering. Any other solicitation or offering of securities shall be made only by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. The Parties reserve the right to withdraw or amend, for any reason, any offering and to reject any subscription agreement for any reason, or for no reason. The communication of this Presentation is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. The Recipient acknowledges that it (a) is aware that the United States securities laws prohibit any person who has material, non-public information concerning a company from purchasing or selling securities of such company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities, (b) is familiar with the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the "Exchange Act"), and (c) will neither use, nor cause any third party to use, this Presentation or any information contained herein in contravention of the Exchange Act, including, without limitation, Rule 10b-5 thereunder. The securities to be issued in the Offerings have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

No representations or warranties, express or implied, are given in, or in respect of, this Presentation. This Presentation is subject to updating, completion, revision, verification and further amendment. None of the Parties or their respective affiliates has authorized anyone to provide interested parties with additional or different information. No securities regulatory authority has expressed an opinion about the securities discussed in this Presentation or determined if this Presentation is truthful, accurate or complete, and it is an offense to claim otherwise.

Disclaimers

Neither Launch nor Minovia nor any of their respective subsidiaries, equity holders, affiliates, representatives, partners, members, directors, officers, employees, advisers or agents (collectively, "Representatives") makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein or any other written, oral or other communications transmitted or otherwise made available to the Recipient in the course of its evaluation of the Transactions, and nothing contained herein shall be relied upon as a promise or representation as to the past or future performance. To the fullest extent permitted by law, none of the Parties nor any of their Representatives shall be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation or its contents, its accuracy or sufficiency, its omissions, its errors, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. In addition, the information contained herein does not purport to contain all of the information that may be required to evaluate the Transactions. The information contained in this Presentation is provided as of the date hereof and may change, and none of the Parties nor any of their Representatives undertakes any obligation to update such information, including in the event that such information becomes inaccurate or incomplete. The general explanations included in this Presentation cannot address, nor is intended to address, any Recipient's specific investment objectives, financial situations, or financial needs.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with any Party or their respective Representatives, as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Parties and each of the Transactions. Recipients of this Presentation should read the definitive documents for the Offerings or the Business Combination and make their own evaluation of the Parties and the Offerings or the Business Combination and of the relevance and adequacy of the information and should make such other investigations as they deem necessary.

Recipients are urged to request any additional information necessary or desirable in making an informed investment decision. Recipients (and their Representatives, if any) are invited, prior to the entry into any definitive documentation with respect to the Offerings or the consummation of the Business Combination, to ask questions of, and receive answers from, the Parties concerning the Transactions and to obtain additional information regarding the Transactions, to the extent the same can be acquired without unreasonable effort or expense, in order to verify the accuracy of the information contained herein.

Confidentiality

This information is being distributed to Recipients on a confidential basis. By receiving this information, Recipients and their affiliates and Representatives agree to maintain the confidentiality of the information contained herein. Without the express prior written consent of each of the Parties, this Presentation and any information contained within it may not be (i) reproduced (in whole or in part), (ii) copied at any time, (iii) used for any purpose other than the evaluation of the Parties and the Transactions, or (iv) provided to any person except a Recipient's employees and advisors with a need to know who are advised of the confidentiality of the information. This Presentation supersedes and replaces all previous oral or written communications between the parties hereto relating to the subject matter hereof.

Disclaimers

Forward-Looking Statements

This Presentation (and any oral statements regarding the subject matter of this Presentation) contains certain forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act with respect to the Parties and the Transactions, including expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding Launch, Minovia, the Transactions and statements regarding the anticipated benefits and timing of the completion of the Transactions; Minovia's goals and growth strategies; Minovia's future business development, results of operations and financial condition; Minovia's ability to compete successfully with its competitors; government policies and regulations relating to Minovia's operations; general economic and business condition; Minovia's ability to attract and retain qualified senior management personnel and employees; Minovia's listing on an applicable stock exchange; expected operating costs of Minovia and its subsidiaries; the satisfaction of closing conditions to the Transactions and the level of redemptions of Launch's public shareholders; and Minovia's expectations, intentions, strategies, assumptions or beliefs about future events, results of operations or performance or that do not solely relate to historical or current facts. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "potential," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions, although not all forward-looking statements contain these words.

Forward-looking statements are predictions, projections and other statements about future events or conditions that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Presentation, including, but not limited to: the risk that the Transactions may not be completed in a timely manner or at all, which may adversely affect the price of Launch's securities; the risk that the Business Combination may not be completed by Launch's business combination deadline; the failure by the Parties to satisfy the conditions to the consummation of the Business Combination, including the approval of Launch's shareholders or the Offerings; failure to realize the anticipated benefits of the Transactions; the level of redemptions of Launch's public shareholders which may reduce the public float of, reduce the liquidity of the trading market of, and/or maintain the quotation, listing, or trading of, the securities of Launch; the failure to obtain or maintain the listing of securities on any stock exchange after closing of the Business Combination; costs related to the Transactions and as a result of Minovia's becoming a public company; changes in business, market, financial, political and regulatory conditions; risks relating to Minovia's anticipated operations and business; risks related to increased competition in the industries in which Minovia operates; risks that after consummation of the Business Combination, Minovia experiences difficulties managing its growth and expanding operations; the outcome of any potential legal proceedings that may be instituted against Launch, Minovia or others following announcement of the Business Combination; and those risk factors discussed in documents of Launch or Minovia filed, or to be filed, with the Securities and Exchange Commission (the "SEC").

You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the final prospectus of Launch dated as of July 11, 2024 and filed by Launch with the SEC on July 12, 2024, Launch's Quarterly Reports on Form 10-Q, Launch's Annual Report on Form 10-K and the registration statement on Form S-4 or F-4 including the proxy statement/prospectus that will be filed by Launch and Minovia, and other documents filed by Launch and Minovia from time to time with the SEC. These filings do or will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. There may be additional risks that neither Launch nor Minovia presently know or that Launch and Minovia currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Although Minovia and Launch believe the expectations reflected in any of the forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the forward-looking statements.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and none of the Parties or any of their Representatives assumes any obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Future financial conditions and results of operations, as well as any forward-looking statements, are subject to change given the inherent risks and uncertainties of market and industry conditions.

None of the Parties or any of its Representatives gives any assurance that either Launch or Minovia will achieve its expectations. The inclusion of any statement in this Presentation does not constitute an admission by Launch, Minovia or any other person that the events or circumstances described in such statement are material.

minovia

Disclaimers

Industry and Market Data

This Presentation has been prepared by the Parties and their Representatives and includes market data and other statistical information from third-party industry publications and sources as well as from research reports prepared for other purposes. This information involves a number of assumptions, estimates and limitations. The industry in which Minovia operates is subject to a high degree of uncertainty and risk due to a variety of factors. Although the Parties believe these third-party sources are reliable as of their respective dates, none of the Parties or any of their respective Representatives has independently verified the accuracy or completeness of this information and cannot assure you of the data's accuracy or completeness. Some data are also based on the Parties' good faith estimates, which are derived from both internal sources and the third-party sources. None of the Parties or their Representatives make any representation or warranty with respect to the accuracy of such information. The Parties expressly disclaim any responsibility or liability for any damages or losses in connection with the use of such information herein. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any registration statement, prospectus, proxy statement or other report or document to be filed or furnished by Launch or Minovia, or any other report or document to be filed with the SEC by Minovia following completion of the Business Combination.

Trademarks and Intellectual Property All trademarks, service marks, and trade names of either Party or their respective affiliates used herein are trademarks, service marks, or registered trade names of such Party or its respective affiliate, respectively, as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners, and their use is not alone intended to, and does not alone imply, a relationship, endorsement, or sponsorship with any Party. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that any Party or the applicable rights owner will not assert, to the fullest extent under applicable law, their rights or the right of the applicable owner or licensor to these trademarks, service marks and trade names.

Additional Information and Where to Find It In connection with the Business Combination, Launch and Minovia intend to file relevant materials with the SEC, including a registration statement on Form S-4 or F-4, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Launch shareholders. Launch will also file other documents regarding the Transactions with the SEC.

Before making any voting or investment decision, investors, shareholders and other interested persons of Launch are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with Transactions carefully and in their entirety as they become available because they will contain important information about the Transactions.

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Launch and Minovia through the website maintained by the SEC at www.sec.gov.

Participants in Solicitation

Launch, Minovia and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies from Launch's shareholders in connection with the Business Combination. A list of the names of such directors and executive officers, and information regarding their interests in the Business Combination and their ownership of Launch's securities are, or will be, contained in Launch's filings with the SEC. Additional information regarding the interests of the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Launch's shareholders in connection with the Business Combination, including and the names and interests of Minovia's directors and executive officers, will be set forth in the proxy statement/prospectus included in the Form S-4 or F-4 for the Business Combination, which is expected to be filed by Launch and Minovia with the SEC. You may obtain free copies of these documents as described in the preceding paragraph.

Minovia and its counsel to review and update risk factors.

Minovia at a Glance

Novel therapeutic platform with classical biotech path and rapid path for revenue generation in longevity

NOVEL CLINICAL STAGE THERAPEUTIC PLATFORM

- ✓ Safety demonstrated in 23 patients treated with MAT (more than 8 years follow up)
- ✓ Multi-systemic improvement and change in disease progression in patients with primary mitochondrial diseases
- ✓ Pre-clinical aging models demonstrate regenerative capabilities and extended lifespan

RAPIDLY ADVANCING CLINICAL PIPELINE

- ✓ Phase 2 in Pearson Syndrome and Phase 1b in Myelodysplastic Syndrome (IND)
- ✓ Clear Path to Fast-Track Approval for Pearson Syndrome established with FDA
- ✓ Novel Biomarkers and Clinical Endpoints Developed

cGMP MANUFACTURING ESTABLISHED

- ✓ cGMP in-house facility fully operational in Israel
- ✓ Cost-effective and scalable supply chain
- ✓ Readiness for T.T to US manufacturing site H2 2025

The scientific excellence and clinical readiness will now be targeted to partnerships with longevity and regenerative medicine clinics

minovia

MAT is an investigational therapy that is undergoing clinical study to verify its safety and effectiveness. Additional information can be found on ClinicalTrials.gov

Expert Leadership Team

Strong board of world experts in the science and business of biotech committed to shape the field of mitochondrial therapies

Board of Directors

John Cox, MBA
Executive Chairman
CEO Dyne Therapeutics (DYN)

Natalie Yivgi-Ohana, Ph.D.
Co-founder, CEO and Director

Ilan Ganot
CEO Alesta Therapeutics
Former Founder and CEO at Solid Bioscience

Ephraim Aharonson, Ph.D.
Co-founder, investor
Ex-Deputy Head, Israel Institute for Biological Research

Shmuel Cabilly, Ph.D.
Biotech entrepreneur and Investor; the inventor of "**The Cabilly Patent**"

Leadership

Natalie Yivgi-Ohana, Ph.D.
Co-founder, CEO and Director
Mitochondrial scientific expert; Led the company since incorporation in 2012

Noa Sher Ph.D.
CSO
Molecular Biologist; Cell and mitochondrial therapy expert

Nadav Eshkol
VP Operations
A cell therapy dev and mfg expert with more than 12 years industry experience

Scientific Advisory Board

Tim Harris, Ph.D.
Chairman of the SAB
Science and business leader; molecular biologist, biochemist and geneticist

Jose-Carlos Gutierrez-Ramos
SVP, CSO, Danaher

Catherine Bollard, MD
Director, Center for Cancer and Immunology Research, CNRI

Martin Picard, Ph.D.
Expert in mitochondrial biology of aging. Associate Professor of Behavioral Medicine in Columbia University Aging Center.

Mitochondrial Dysfunction and the Interrelationship Between Aging and Disease

Mitochondrial Dysfunction is a Hallmark of Aging	Reduced ATP production, increased oxidative stress, and accumulation of damaged mitochondria contribute to cellular decline and organ dysfunction
From Rare Diseases to Aging-Related Conditions	Mitochondrial defects, seen in genetic mitochondrial diseases, also play critical roles in neurodegeneration, muscle weakness, metabolic disorders, anemia and immune system decline associated with Aging
Minovia's Approach: Restoring Core Mitochondrial Function	**Clinical-Stage Mitochondrial Technology** with demonstrated efficacy in rare mitochondrial diseases **Novel Blood Mitochondrial Biomarkers** that enable early detection and tracking of mitochondrial health **Longevity & Regenerative Medicine Platform** of mitochondrial restoration for healthy lifespan extension



By restoring mitochondrial function, Minovia aims to unlock a new frontier in treating age-related diseases and redefining longevity medicine

Lopez-Otin 2016 Cell; Huanzheng 2019 Cells

minovia

Mitochondrial Augmentation Unlocks Healthspan

We are not just treating symptoms—we are restoring life at the cellular level



A Scientific Breakthrough: Minovia's Mitochondrial Augmentation Technology (MAT)



For decades, scientists believed that mitochondria were static, confined to the cells they originated in.
Minovia has shattered that assumption

Minovia Invented a Process of Mitochondrial Transfer into Stem Cells

💡 **Demonstrated in Leading Scientific Research:** First observed in **Clark & Shay (Nature, 1982);** Further validated by **King & Attardi (Cell, 1988);** recently published by **Jacoby and Minovia *Nat Regen Med* 2021**

How It Works:

🔬 **Mitochondria Enter Cells** → Healthy mitochondria naturally integrate into recipient cells

🧬 **Mitochondrial Quality Control renewed** → Damaged mitochondria are replenished with healthy mitochondria

⚡ **Restore Cellular Energy & Function** → Cells regain their ability to produce energy, combat stress, and sustain normal function

🔄 **Enable Mitochondrial Transfer Between Cells** → Healthy mitochondria propagate, spreading their benefits across tissues

Minovia's Breakthrough

A **proprietary process** to harness natural mitochondrial transfer, creating a **scalable, regulatory-backed therapy** to restore function in mitochondrial diseases and aging-related dysfunction

minovia

Longevity Leader with Differentiated Value

Mitochondrial Augmentation Technology aims to provide excessive value to patients, backed by strong scientific and clinical foundations



A Breakthrough Pathway: From Rare Diseases to Aging

Minovia's approach is not just another anti-aging theory—it's a regulatory-backed, science-driven strategy to redefine aging as a treatable condition

Aging affects every one of us—and at its core, it is driven by **mitochondrial dysfunction.** As we age, our mitochondria deteriorate, leading to cellular decline, loss of function, and age-related diseases



Minovia is solving this problem.

✓ **Proven Strategy:** Establish **safety and efficacy** by first targeting **genetic Primary Mitochondrial Diseases (PMD)**

✓ **Regulatory Pathway:** Expand to **age-related mitochondrial dysfunction** as mitochondrial therapy is approved

✓ **Scientific Validation:** **Prove, using novel biomarkers, that aging is, at its core, a mitochondrial disease**

minovia

MAT is an investigational therapy that is undergoing clinical study to verify its safety and effectiveness. Additional information can be found on ClinicalTrials.gov

Mitochondrial Augmentation Technology: The Solution



The Mitochondria: Powerful Organelles

Critical for cellular metabolism, biosynthesis, and homeostasis

Mitochondria are the **powerhouses of life**—fuelling every cell, tissue, and organ in the body. When mitochondria fail, **every organ system suffers.**

Genetic mitochondrial diseases provide a clear model of what happens when mitochondrial function breaks down—offering **a window into the aging process itself**

Age-related mitochondrial damage follows a similar pattern, leading to:

- 🧠 **Brain decline** → Neurodegeneration, cognitive impairment (Alzheimer's, Parkinson's)
- 💪 **Muscle weakness** → Frailty, sarcopenia, loss of mobility
- 🫀 **Heart dysfunction** → Cardiovascular disease, heart failure
- 🩸 **Blood and Immune system failure** → Anemia, infections, slower healing
- 🪫 **Metabolic disorders** → Type 2 diabetes, fatty liver disease



minovia

Monzel, Nat Met 2023; Suomalainen mitochondrion 2018; Tyynismaa EMBO Reports 2009; Srivastave, Genes 2017

Lead Product MNV-201: Autologous Stem Cells Enriched with Allogeneic Placental Mitochondria

A first-in-class mitochondrial therapy designed to restore cellular function

Key Advantages:

- ✓ **Highly Scalable Manufacturing** → Designed for efficient, large-scale production
- ✓ **Minimally Invasive & Streamlined Process** → Rapid **vein-to-vein** delivery within 72 hours
- ✓ **Proven Safety Profile** → No conditioning required, reducing patient risk



minovia

HSCs: Hematopoietic stem cells; DS: Drug Substance; DP: Drug Product: IV: intra-Venus

MAT is an investigational therapy that is undergoing clinical study to verify its safety and effectiveness. Additional information can be found on ClinicalTrials.gov

From Rare Disease to Longevity: The Path to Develop Therapies for Healthy Aging

Minovia is pursuing a **strategic, regulatory-backed approach** that begins with rare genetic mitochondrial diseases and expands to broader aging-related conditions



Pitceathly RD, Rahman S, Hanna MG (2012 Neuromuscul Disord

David P. Steensma, MD., Mayo Clin Proc. 2015;90(7):969-983

minovia

MAT is an investigational therapy that is undergoing clinical study to verify its safety and effectiveness. Additional information can be found on ClinicalTrials.gov

Competitive Landscape: Key Players

Minovia is the first clinical-stage company in the emerging mitochondrial transplantation field

Pre-Clinical Mitochondrial Transplantation Companies

CELLVIE	Therapeutic mitochondrial transplant to compromised cells
PAEAN BIOTECHNOLOGY	Mitochondria complex with scFv against cancer & cell therapy with mitochondria-enriched PMBC / NK cells
LUCA Science Inc.	Functional mitochondria as therapeutic agents
IMEL Biotherapeutics	Autologous mitochondria-replaced T cells as cell therapy

Minovia's unique value proposition

As the first company, Minovia controls the IP related to mitochondrial transplantation; the MAT platform is safe and scalable relative to other players

Minovia Clinicaltrials.gov

minovia

Gene and Cell Therapy, Aging and Mitochondria

The advantages of Minovia's technology over multi-billion $ companies

REATA PHARMACEUTICALS	**Successful Mitochondrial Company**	Reata develops therapies for rare mitochondrial diseases. Lead product approved by FDA for Friederich Ataxia. Acquired by Biogen In 2023 for **$6.5B**	Minovia's **highly scalable and cost-efficient** platform could address **multiple diseases in parallel**, both rare and common
BridgeBio	**Genetic Diseases**	Commercial and Clinical stage biotech with several programs in genetic diseases **$6.12B** Market Cap	Minovia's MAT platform was designed to be safe by overcoming major limitations of genetic therapies; this allows **multiple treatments** which boosts the financing model
ALTOS™	**Aging Company**	Pre-clinical stage biotech company aiming to reverse aging and rejuvenate cells. No drug targets announced yet. Latest valuation was **$6.33B** (2024)	Minovia is in **clinical stage** with **accelerated approval path** in rare diseases and immediate longevity market opportunity
Beam THERAPEUTICS	**Rare Genetic Diseases**	Clinical stage gene editing company with several programs in rare genetic diseases. **$2.36B** Market Cap	Minovia does not require gene editing disease-specific tools, making our therapy **safe and applicable for multiple diseases**

Davies, Human Reproduction, 2019

minovia

Revolutionizing Longevity